Press Release: HHS Cancels VaxGen's Anthrax Vaccine Contract

HHS Cancels VaxGen's Anthrax Vaccine Contract

BRISBANE, Calif., Dec. 19 -- VaxGen, Inc. announced today that the Department of Health and Human Services (HHS) has terminated for default the company's contract to provide 75 million doses of a modern anthrax vaccine for civilian biodefense. HHS based the decision on its determination that VaxGen "failed to successfully cure the condition endangering performance and failed to" meet a milestone imposed by HHS that required VaxGen to initiate a clinical trial of the vaccine candidate by December 18, 2006.